查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1868925

標靶治療市場按產品類型、給藥途徑和最終用戶分類 - 全球預測 2025-2032

Targeted Therapy Market by Product Type, Route Of Administration, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，標靶治療市場將成長至 1,218 億美元，複合年成長率為 7.72%。

關鍵市場統計數據
基準年 2024 671.6億美元
預計年份：2025年 724.1億美元
預測年份 2032 1218億美元
複合年成長率 (%) 7.72%

簡明扼要地概述了不斷發展的標靶治療生態系統，將科學突破與領導者的營運、監管和商業要務聯繫起來。

透過將分子層面的洞見與治療方案設計相結合，標靶治療正在重新定義臨床醫生和研發人員應對複雜疾病的方式。近年來，包括抗體藥物複合體、單株抗體、蛋白質分解劑和小分子抑制劑在內的多種治療方法取得了突破性進展，從概念驗證階段邁向了日益成熟的臨床計畫。因此，藥物發現、開發和商業化等各環節的相關人員必須適應更快的迭代週期、更深入的生物標記整合以及更為細緻的監管互動。本文概述了影響該領域發展的關鍵因素，並展望了近期戰術性重點。

科學、監管和商業性創新相互融合，正在重塑標靶治療領域的治療方法和業務重點。

過去幾年，標靶治療領域發生了翻天覆地的變化，加速了新型治療方法的研發，同時也帶來了新的營運挑戰。蛋白質工程和偶聯化學技術的進步使得抗體藥物複合體（ADC）成為選擇性遞送細胞毒性藥物的主要治療方法。同時，單株抗體向全人源化和人源化結構的演進降低了免疫抗原性，延長了治療療程。此外，分子膠（MG）和蛋白水解靶向嵌合體（PTC）等標靶蛋白水解技術的成熟，為調控以往難以標靶的標靶開闢了新的途徑，拓展了治療選擇。

分析2025年公佈的累積貿易和關稅趨勢及其對生物製藥採購、生產和患者獲取策略的連鎖影響

2025年宣布的累積關稅和貿易調整措施的實施，為標靶治療價值鏈帶來了新的複雜性，影響採購、生產和分銷決策。原料、特殊試劑和某些生物製藥成分的關稅變化推高了實際到岸成本，促使採購團隊重新評估其供應商佈局。這種壓力通常會導致與契約製造的談判週期延長，並促使企業重新關注雙重籌資策略，以維持臨床和商業性的連續性。此外，關稅帶來的成本壓力也影響新設施建設和技術投資的資本分配決策。

整合產品模式、給藥途徑和終端用戶交付方式等細分市場洞察，以指導研發優先排序和商業化策略。

有效的細分能夠識別具有治療獲益和商業性回報的領域，從而實現跨產品、給藥途徑和最終用戶領域的投資組合優先排序。依產品類型分類，抗體藥物複合體(ADC)、單株抗體、蛋白水解物和小分子抑制劑可分為不同的類別，每種類別都有不同的開發、生產和商業化要求。在抗體藥物複合體(ADC) 中，靶向 CD22 和 HER2 的藥物在有效載荷選擇和目標結合策略上存在差異，這會影響連接子化學和細胞毒性有效載荷的選擇。單株抗體進一步細分為嵌合體、全人源型和人源化型，影響免疫抗原性風險、給藥頻率和監管預期。蛋白水解物包括分子黏合劑和 PROTAC，它們具有不同的選擇性特徵和臨床前評估途徑。同時，小分子抑制劑涵蓋從 PARP 抑制劑到蛋白酶體抑制劑和蛋白酪氨酸激酶抑制劑等多種類型，每種抑制劑都需要不同的藥理特性和伴隨診斷方法。

區域洞察：分析美洲、歐洲、中東和非洲以及亞太地區的市場動態將如何影響開發、市場准入和供應鏈策略。

地理洞察對於全球規劃至關重要，因為區域趨勢會影響從臨床開發策略到供應鏈配置以及與支付方互動等各方面。美洲地區擁有不同的監管路徑和支付體系，但往往在創新治療方法的早期應用和基於價值的合約試點方面處於領先。因此，製造商應優先考慮產生可靠的臨床證據和支付方參與框架，以證明其療效和長期結果。北美地區的生產能力和先進的臨床試驗基礎設施支持複雜治療方法的快速患者招募，但國內採購和關稅因素可能會影響後期生產的位置。

行業領導者正在採取策略性企業行動並進行產能投資，以將技術創新轉化為具有臨床意義的治療方法和永續的商業性優勢。

業界領導企業正採取各種策略性舉措，以充分發揮標靶治療的潛力，同時應對相關的科學和商業性複雜性。許多機構正在加速投資於標準化偶聯技術、抗體設計和分解化學的平台，以降低技術風險並加快臨床試驗進程。他們還與生物技術公司、學術機構和合約開發組織建立合作關係，以利用這些機構的專業知識，而無需承擔全部內部開發成本。這些夥伴關係模式支持靈活的產能擴張，並且能夠快速回應特定療法的需求波動。

針對標靶治療領導企業的實用跨職能建議，包括整合生物標記主導的開發、彈性供應鏈和以病人為中心的商業化。

致力於最大化標靶治療價值的領導者應實施切實可行的跨職能措施，協調科學重點、商業性現實和供應鏈韌性。首先，在臨床開發早期階段整合生物標記策略和衛生經濟學，確保試驗能夠產生支付方所需的證據。協調這些職能可以減少後期延誤，並增強價值提案。其次，透過選擇區域契約製造合作夥伴並設計能夠實現關鍵組件互換性的平台，實現採購和生產多元化，從而降低關稅衝擊和短期供應中斷帶來的風險。

透明的混合方法研究框架，結合相關利益者訪談、臨床和專利分析、供應鏈圖譜繪製以及情境檢驗，確保了研究結果的可靠性。

本研究融合了定性和定量方法，旨在深入了解標靶治療的動態發展。它結合了與關鍵相關人員的直接對話、系統的二手資料研究和技術綜述。一手研究包括對臨床研究人員、監管專家、生產經理、支付方和分銷專家進行深度訪談，以揭示實際操作中的限制和新興的最佳實踐。這些訪談構成了主題編碼的基礎，識別出反覆出現的營運痛點，例如低溫運輸薄弱環節、監管差異以及支付方的證據要求。

從綜合視角和策略角度分析科學進步、供應鏈因素和支付方期望如何決定標靶治療的成功。

總之，標靶治療領域正處於轉折點，科學創新、營運複雜性和商業性審查在此交匯融合。抗體藥物複合體、單株抗體、蛋白質分解劑和小分子抑制劑的進步拓展了研發人員的工具箱，但要實現治療和商業性的成功，需要研發、生產、監管事務和醫保支付等各環節的協調合作。貿易和關稅的變化帶來了新的營運挑戰，需要更詳細的供應鏈規劃和策略採購決策；而監管和報銷框架的區域差異則要求量身定做的市場推廣策略。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧應用於生物標記發現，以實現個人化標靶治療
  • 針對多種腫瘤抗原的雙特異性抗體的出現，有助於克服抗藥性機制
  • 擴大標靶表觀遺傳修飾因子的小分子抑制劑在精準腫瘤學的應用
  • 監管獎勵促進針對罕見致癌性突變的小眾標靶治療的開發
  • 透過位點特異性有效載荷偶聯技術推進抗體藥物複合體(ADC) 的創新
  • 數位生物標記合作投資趨勢，旨在最佳化標靶治療的患者分層
  • 一種個人化的新抗原疫苗平台，可與標靶治療方案互補，以增強免疫反應。

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按產品類型標靶治療市場

  • 抗體藥物複合體
    • CD22標靶
    • HER2靶點
  • 單株抗體
    • 嵌合體體
    • 完全人類
    • 人性化
  • 蛋白質分解劑
    • 分子黏合劑
    • 進攻
  • 小分子抑制劑
    • PARP抑制劑
    • 蛋白酶體抑制劑
    • 蛋白酪氨酸激酶抑制劑

第9章 按給藥途徑標靶治療市場

  • 靜脈注射
  • 口服
  • 皮下注射

第10章 按最終用戶標靶治療市場

  • 居家醫療
  • 醫院藥房
  • 零售藥房
  • 專科診所

第11章 各地區的標靶治療市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章標靶治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國標靶治療市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Pfizer Inc.
    • Merck & Co., Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca PLC
    • AbbVie Inc.
    • Amgen Inc.
    • Johnson & Johnson
    • Gilead Sciences, Inc.
Product Code: MRR-CA7E340319CF

The Targeted Therapy Market is projected to grow by USD 121.80 billion at a CAGR of 7.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 67.16 billion
Estimated Year [2025] USD 72.41 billion
Forecast Year [2032] USD 121.80 billion
CAGR (%) 7.72%

A concise orientation to the evolving targeted therapy ecosystem that connects scientific breakthroughs with operational, regulatory, and commercial imperatives for leaders

Targeted therapies are redefining how clinicians and developers approach complex diseases by aligning molecular insights with therapeutic design. Recent scientific advances have pushed modalities such as antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors from proof-of-concept into increasingly sophisticated clinical programs. As a result, stakeholders across discovery, development, and commercialization must adapt to faster iteration cycles, deeper biomarker integration, and more nuanced regulatory dialogues. This introduction frames the critical forces shaping the field and sets expectations for near-term tactical priorities.

Investors and R&D leaders now judge programs not only on biological rationale but also on manufacturability, supply chain robustness, and reimbursement pathways. Clinical teams emphasize patient selection and companion diagnostics to improve trial efficiency and therapeutic impact, while manufacturing groups prioritize platform consistency and scalable processes to reduce variability. In parallel, payers and health systems increasingly demand real-world evidence and outcomes-based contracting to justify premium pricing for novel modalities. These converging pressures create both friction and opportunity: organizations that align scientific excellence with operational execution will capture disproportionate value.

Transitioning from early discovery to widespread adoption requires deliberate alignment across cross-functional teams. This report begins by outlining transformational shifts in science and market structure, then explores regulatory and trade headwinds, segment-level implications, regional dynamics, and strategic recommendations intended to inform immediate actions and longer-term planning.

How converging scientific, regulatory, and commercial innovations are reshaping therapeutic modalities and operational priorities across the targeted therapy landscape

The last several years have produced transformative shifts that are remapping the targeted therapy landscape, accelerating novel modalities while raising new operational imperatives. Technological advances in protein engineering and conjugation chemistry have elevated antibody drug conjugates into a leading modality for delivering cytotoxic payloads selectively, while monoclonal antibody evolution toward fully human and humanized constructs has reduced immunogenicity and enabled longer treatment windows. Simultaneously, the maturation of targeted protein degradation-through molecular glues and proteolysis targeting chimeras-introduces routes to modulate previously intractable targets, broadening the therapeutic opportunity set.

These scientific gains intersect with innovations in small molecule design, where tailored inhibitors such as PARP, proteasome, and tyrosine kinase agents offer complementary mechanisms for multi-modal regimens. At the same time, digital tools and artificial intelligence accelerate lead identification and predictive modeling, shortening development cycles and improving candidate selection. Regulatory frameworks are adapting to these modalities by offering more targeted guidance on combination approaches, biomarker-driven approvals, and adaptive trial designs, yet variability in regional expectations is prompting sponsors to design programs with parallel regulatory engagement.

Commercially, payers and providers are demanding clearer evidence of comparative effectiveness and value-based pricing models, which drives closer alignment between clinical development and health economics planning. Manufacturing and cold-chain logistics improvements are enabling new route-of-administration strategies, particularly increased attention to subcutaneous and home-administered formulations that improve patient convenience and lower system costs. The net effect is a landscape where innovation is rapid, but success increasingly depends on integrated scientific, regulatory, and commercial execution.

Analyzing the cumulative trade and tariff dynamics announced for 2025 and their cascading effects on biopharmaceutical sourcing, manufacturing, and patient access strategies

The introduction of cumulative tariffs and trade adjustments announced for 2025 has introduced a new layer of complexity across the targeted therapy value chain, affecting sourcing, manufacturing, and distribution decisions. Tariff changes on raw materials, specialized reagents, and certain biologics-related components increase effective landed costs and prompt procurement teams to reassess supplier footprints. These pressures often translate into longer negotiation cycles with contract manufacturers and a renewed emphasis on dual-sourcing strategies to maintain clinical and commercial continuity. Moreover, tariff-driven cost pressures influence capital allocation decisions for new facility builds and technology investments.

Manufacturers facing increased import duties for key inputs have adopted several mitigation strategies, including reshoring select production steps closer to end markets, qualifying local suppliers where possible, and redesigning supply chains to reduce reliance on tariff-exposed nodes. Regulatory harmonization efforts and free trade agreements remain uneven, so companies must navigate a patchwork of customs procedures and compliance requirements that can delay batch release and increase lead times. For programs reliant on time-sensitive biologics or cold-chain logistics, even modest tariff-related delays can disrupt clinical trial timelines and product launches, which in turn impacts forecasting and inventory policies at distributors and hospitals.

In response, senior leaders are recalibrating vendor contracts to include tariff pass-through clauses and investing in supply chain transparency tools to model exposure across scenarios. Strategic sourcing now requires closer collaboration between commercial, regulatory, and procurement teams to optimize total landed cost while preserving product integrity and patient access. The cumulative effect of these trade measures is to accelerate existing trends toward regionalization of production and enhanced supply chain resilience, with implications for pricing strategies, partner selection, and manufacturing footprint optimization.

Segment-focused insights that integrate product modality, administration route, and end-user delivery considerations to inform development prioritization and commercialization tactics

Effective segmentation clarifies where therapeutic and commercial returns will concentrate and informs portfolio prioritization across product, administration route, and end-user domains. When viewed through product type, the landscape differentiates antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors, each with distinct development, manufacturing, and commercialization demands. Within antibody drug conjugates, agents directed at CD22 and HER2 represent divergent payload selection and target engagement strategies that influence linker chemistry and cytotoxic payload choices. Monoclonal antibodies subdivide into chimeric, fully human, and humanized formats, affecting immunogenicity risk, dosing frequency, and regulatory expectations. Protein degraders encompass molecular glues and PROTACs, which differ in selectivity profiles and preclinical assessment pathways, while small molecule inhibitors range from PARP inhibitors to proteasome and tyrosine kinase inhibitors, each requiring different pharmacology and companion diagnostic approaches.

Routes of administration add another layer of strategic differentiation, spanning intravenous, oral, and subcutaneous delivery. Intravenous therapies often necessitate hospital-based administration and complex cold-chain logistics, while oral agents increase outpatient convenience and adherence considerations. Subcutaneous formulations are gaining prominence as a patient-friendly alternative that can reduce infusion center burden and enable home-based care models. End-user segmentation further refines go-to-market and support needs, with home care, hospital pharmacy, retail pharmacy, and specialty clinics each presenting unique distribution, reimbursement, and patient support requirements. Home care models require robust patient education and remote monitoring, hospital pharmacy environments demand streamlined formulary access and inpatient logistics, retail pharmacies offer broad outpatient reach but require clear dispensing pathways, and specialty clinics provide concentrated clinical expertise and can facilitate complex care pathways.

Understanding the intersection across these dimensions enables sponsors to tailor development and commercialization tactics, align clinical trial designs with likely real-world administration settings, and structure stakeholder engagement plans that reflect where and how therapies will be delivered and reimbursed.

Regional intelligence spotlighting how Americas, Europe Middle East & Africa, and Asia-Pacific market dynamics influence development, access, and supply chain strategies

Regional dynamics shape everything from clinical development strategies to supply chain configuration and payer interactions, making geographic insight indispensable for global planning. In the Americas, regulatory pathways and payer systems are highly varied, but the region often leads in early adoption of innovative therapies and value-based contracting pilots; manufacturers should therefore prioritize robust clinical evidence generation and payer engagement frameworks that demonstrate comparative effectiveness and long-term outcomes. North American manufacturing capacity and advanced clinical trial infrastructure support rapid enrollment for complex modalities, but domestic sourcing and tariff considerations can influence where late-stage production is sited.

Europe, Middle East & Africa present a mosaic of regulatory expectations and reimbursement mechanisms that require tailored market entry strategies. European health technology assessment bodies frequently demand rigorous health economic data and may negotiate centralized procurement for high-cost therapies, while reimbursement timelines can vary substantially between markets. The Middle East and Africa offer pockets of high unmet need and concentrated procurement initiatives, yet accessibility and local regulatory capacity vary widely, prompting sponsors to adopt differentiated commercial models and targeted access programs.

Asia-Pacific continues to expand clinical development capacity and local manufacturing capabilities, with several markets emphasizing domestic innovation and regulatory modernization. Countries across the region are increasingly receptive to data generated from local patient populations and are investing in infrastructure that supports large-scale oncology and specialty care trials. Pricing and reimbursement policies differ markedly between public and private systems, so sponsors should design regional strategies that balance localized evidence generation with efficient regulatory pathways. Across regions, the convergence of digital health adoption and decentralized trial methodologies presents opportunities to harmonize patient recruitment, monitoring, and long-term outcomes collection at scale.

Strategic corporate moves and capability investments industry leaders are deploying to convert modality innovation into clinically meaningful therapies and sustainable commercial advantage

Industry leaders are deploying a range of strategic moves to capture the promise of targeted therapies while managing the attendant scientific and commercial complexity. Many organizations are accelerating platform investments that standardize conjugation technologies, antibody engineering, and degradation chemistries to reduce technical risk and shorten time to clinic. Others are forging collaborations across biotech partners, academic centers, and contract development organizations to access specialized capabilities without assuming the full cost of in-house development. These partnership models support flexible capacity scaling and enable rapid response as modality-specific demand shifts.

Commercial strategies now emphasize integrated launch planning that brings clinical development, regulatory engagement, health economics, and market access teams together earlier in the lifecycle. Leaders invest in real-world evidence generation and outcomes tracking to demonstrate value to payers and providers, and they deploy patient support services to promote adherence and optimize clinical outcomes. On the manufacturing front, companies are diversifying supplier bases, qualifying secondary manufacturing sites, and expanding fill-finish capabilities to mitigate supply disruption risks.

Pipeline management has become more selective, with sponsors prioritizing indications and combinations that maximize therapeutic differentiation and align with feasible reimbursement pathways. Talent strategies focus on hiring scientists and executives with cross-functional experience in biologics, regulatory affairs, and commercial operations. The net effect is a more disciplined, partnership-driven, and execution-focused industry posture that seeks to translate scientific promise into durable therapeutic and commercial success.

Actionable cross-functional recommendations to align biomarker-driven development, resilient supply chains, and patient-centric commercialization for leaders in targeted therapy

Leaders seeking to maximize value in targeted therapy should adopt a set of actionable, cross-functional measures that align scientific priorities with commercial realities and supply chain resilience. First, integrate biomarker strategy and health economics early in clinical development to ensure trials generate the evidence payers require; connecting these functions reduces later-stage delays and strengthens value narratives. Second, diversify sourcing and manufacturing by qualifying regional contract manufacturing partners and by designing platforms that permit interchangeability of critical components; this reduces exposure to tariff shocks and short-term supply interruptions.

Third, prioritize patient-centric administration strategies by investing in subcutaneous formulation development and patient support infrastructure that enable home-based care where clinically appropriate. Fourth, pursue strategic collaborations to access specialized modalities such as molecular glues or PROTAC chemistry while preserving optionality through staged investment and clear milestone gating. Fifth, engage proactively with regulatory authorities across key jurisdictions to align on adaptive trial designs and biomarker-driven approval pathways, reducing the risk of divergent requirements and costly trial amendments.

Finally, operationalize data and analytics to monitor supply chain exposure, clinical trial progress, and real-world outcomes in near real time; these capabilities enable faster course corrections and more informed commercial rollouts. Collectively, these actions help organizations navigate complexity, preserve optionality, and accelerate the translation of scientific advances into patient benefit and sustained commercial performance.

A transparent mixed-methods research framework combining stakeholder interviews, clinical and patent analysis, supply chain mapping, and scenario-based validation to ensure robust insights

This research synthesizes qualitative and quantitative approaches to produce a nuanced view of targeted therapy dynamics, combining primary stakeholder engagement with structured secondary analysis and technical review. Primary research included in-depth interviews with clinical investigators, regulatory specialists, manufacturing leaders, payers, and distribution experts to surface practical constraints and emerging best practices. These dialogues informed thematic coding and identified recurring operational pain points such as cold-chain vulnerability, regulatory heterogeneity, and payer evidence expectations.

Secondary analysis encompassed peer-reviewed literature, clinical trial registries, patent filings, and publicly available regulatory guidance to validate scientific trends and modality-specific technical requirements. Supply chain mapping leveraged public customs data and industry logistics reporting to trace typical component flows and identify tariff-sensitive nodes. Additionally, product development case studies and manufacturing due diligence informed assessments of platform readiness and scale-up risk.

Analytical methods included cross-sectional synthesis to compare modality characteristics, scenario modeling to evaluate tariff and supply disruption impacts, and triangulation across data sources to ensure robustness. Wherever possible, findings were stress-tested against recent regulatory decisions, clinical readouts, and announced capacity investments to ensure recommendations reflect operational realities. This mixed-methods approach offers a replicable framework for translating scientific advances into strategic priorities while acknowledging uncertainty and preserving managerial flexibility.

Synthesis and strategic outlook summarizing how scientific advances, supply chain considerations, and payer expectations will determine success in targeted therapy

In closing, the targeted therapy field stands at an inflection point where scientific ingenuity meets operational complexity and commercial scrutiny. Advances across antibody drug conjugates, monoclonal antibodies, protein degraders, and small molecule inhibitors have expanded the toolkit available to developers, but realizing therapeutic and commercial promise requires coordinated action across development, manufacturing, regulatory, and payer engagement functions. Trade and tariff changes add a new operational layer that compels more granular supply chain planning and strategic sourcing decisions, while regional heterogeneity in regulatory and reimbursement frameworks necessitates tailored go-to-market approaches.

Organizations that invest early in integrated evidence generation, diversify manufacturing footprints, and design patient-centered administration strategies will improve their odds of successful adoption. Partnerships remain a powerful mechanism to access specialized capabilities and to share risk, and leaders who combine platform investments with selective external collaborations are best positioned to scale efficiently. Ultimately, targeted therapies will continue to reshape treatment paradigms, but success will hinge on the ability to translate molecular innovation into reproducible clinical outcomes, reliable supply, and validated value to payers and providers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence in biomarker discovery for personalized targeted therapies
  • 5.2. Emergence of bispecific antibodies targeting multiple tumor antigens to overcome resistance mechanisms
  • 5.3. Expansion of small molecule inhibitors targeting epigenetic modifiers in precision oncology
  • 5.4. Regulatory incentives accelerating development of niche targeted therapies for rare oncogenic mutations
  • 5.5. Momentum in antibody-drug conjugate innovation with site-specific payload conjugation techniques
  • 5.6. Investment trends in digital biomarker partnerships to optimize patient stratification for targeted therapeutics
  • 5.7. Personalized neoantigen vaccine platforms complementing targeted therapy regimens to enhance immune response

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Therapy Market, by Product Type

  • 8.1. Antibody Drug Conjugates
    • 8.1.1. Cd22 Directed
    • 8.1.2. Her2 Directed
  • 8.2. Monoclonal Antibodies
    • 8.2.1. Chimeric
    • 8.2.2. Fully Human
    • 8.2.3. Humanized
  • 8.3. Protein Degraders
    • 8.3.1. Molecular Glues
    • 8.3.2. Protacs
  • 8.4. Small Molecule Inhibitors
    • 8.4.1. Parp Inhibitors
    • 8.4.2. Proteasome Inhibitors
    • 8.4.3. Tyrosine Kinase Inhibitors

9. Targeted Therapy Market, by Route Of Administration

  • 9.1. Intravenous
  • 9.2. Oral
  • 9.3. Subcutaneous

10. Targeted Therapy Market, by End User

  • 10.1. Home Care
  • 10.2. Hospital Pharmacy
  • 10.3. Retail Pharmacy
  • 10.4. Specialty Clinic

11. Targeted Therapy Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Targeted Therapy Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Targeted Therapy Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. F. Hoffmann-La Roche Ltd
    • 14.3.2. Novartis AG
    • 14.3.3. Pfizer Inc.
    • 14.3.4. Merck & Co., Inc.
    • 14.3.5. Bristol-Myers Squibb Company
    • 14.3.6. AstraZeneca PLC
    • 14.3.7. AbbVie Inc.
    • 14.3.8. Amgen Inc.
    • 14.3.9. Johnson & Johnson
    • 14.3.10. Gilead Sciences, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. TARGETED THERAPY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. TARGETED THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TARGETED THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TARGETED THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED THERAPY MARKET SIZE, BY CD22 DIRECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED THERAPY MARKET SIZE, BY HER2 DIRECTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED THERAPY MARKET SIZE, BY CHIMERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED THERAPY MARKET SIZE, BY FULLY HUMAN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED THERAPY MARKET SIZE, BY HUMANIZED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED THERAPY MARKET SIZE, BY MOLECULAR GLUES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTACS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED THERAPY MARKET SIZE, BY PARP INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED THERAPY MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED THERAPY MARKET SIZE, BY TYROSINE KINASE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED THERAPY MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED THERAPY MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TARGETED THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TARGETED THERAPY MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TARGETED THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 148. AMERICAS TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 149. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. AMERICAS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 151. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 152. AMERICAS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 153. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 154. AMERICAS TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 168. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 170. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 172. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 184. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 186. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 188. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 190. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 232. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 234. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 236. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 238. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 243. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AFRICA TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. AFRICA TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 247. AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 248. AFRICA TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 249. AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 250. AFRICA TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 251. AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 252. AFRICA TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 253. AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 254. AFRICA TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL TARGETED THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. ASEAN TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. ASEAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. ASEAN TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. ASEAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 282. ASEAN TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 283. ASEAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 284. ASEAN TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 285. ASEAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 286. ASEAN TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 287. ASEAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 288. ASEAN TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 293. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 294. GCC TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 295. GCC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. GCC TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. GCC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 298. GCC TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 299. GCC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 300. GCC TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 301. GCC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 302. GCC TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 303. GCC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 304. GCC TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 305. GCC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 306. GCC TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 307. GCC TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 308. GCC TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY PROTEIN DEGRADERS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY SMALL MOLECULE INHIBITORS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION TARGETED THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 325. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. BRICS TARGETED THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. BRICS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. BRICS TARGETED THERAPY MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 329. BRICS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2018-2024 (USD MILLION)
  • TABLE 330. BRICS TARGETED THERAPY MARKET SIZE, BY ANTIBODY DRUG CONJUGATES, 2025-2032 (USD MILLION)
  • TABLE 331. BRICS TARGETED THERAPY MARKE